- Home
- BNR vs UNCY Comparison
BNR vs UNCY Comparison
Compare BNR & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNR
- UNCY
- Stock Information
- Founded
- BNR 2014
- UNCY 2016
- Country
- BNR China
- UNCY United States
- Employees
- BNR N/A
- UNCY N/A
- Industry
- BNR Medical Specialities
- UNCY Biotechnology: Pharmaceutical Preparations
- Sector
- BNR Health Care
- UNCY Health Care
- Exchange
- BNR Nasdaq
- UNCY Nasdaq
- Market Cap
- BNR 38.3M
- UNCY 91.0M
- IPO Year
- BNR 2020
- UNCY 2021
- Fundamental
- Price
- BNR $4.93
- UNCY $4.62
- Analyst Decision
- BNR
- UNCY Strong Buy
- Analyst Count
- BNR 0
- UNCY 4
- Target Price
- BNR N/A
- UNCY $63.75
- AVG Volume (30 Days)
- BNR 20.1K
- UNCY 1.2M
- Earning Date
- BNR 08-21-2025
- UNCY 08-13-2025
- Dividend Yield
- BNR N/A
- UNCY N/A
- EPS Growth
- BNR N/A
- UNCY N/A
- EPS
- BNR N/A
- UNCY N/A
- Revenue
- BNR $72,112,038.00
- UNCY N/A
- Revenue This Year
- BNR $136.32
- UNCY N/A
- Revenue Next Year
- BNR N/A
- UNCY $1,458.53
- P/E Ratio
- BNR N/A
- UNCY N/A
- Revenue Growth
- BNR 0.53
- UNCY N/A
- 52 Week Low
- BNR $2.18
- UNCY $2.02
- 52 Week High
- BNR $7.90
- UNCY $11.00
- Technical
- Relative Strength Index (RSI)
- BNR 76.57
- UNCY 40.60
- Support Level
- BNR $3.06
- UNCY $4.31
- Resistance Level
- BNR $4.96
- UNCY $5.55
- Average True Range (ATR)
- BNR 0.25
- UNCY 0.57
- MACD
- BNR 0.15
- UNCY -0.08
- Stochastic Oscillator
- BNR 98.16
- UNCY 10.92
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a biotechnology company dedicated to developing treatments for certain medical conditions. It is focusing on kidney diseases. The company's manufactures drug, Renazorb, is a novel phosphate-binding agent being developed for the treatment of hyperphosphatemia. Unicycive's other drug, UNI-494, is a new chemical entity with the issued composition of matter patent protection in late preclinical development for the treatment of acute kidney injury. Company's pipeline comprised of two product candidates: Oxylanthanum Carbonate and UNI-494.